文献速递肿瘤 PET/CT甲状腺核医学

HER2阳性早期乳腺癌中[18F]FDG-PET病灶检测的临床病理与分子预测因素:RESPONSE,随机PHERGain试验的子研究

Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-04-08

RESPONSE子研究纳入PHERGain试验中经MRI评估肿瘤>1.5 cm的500例HER2阳性早期乳腺癌患者,评估[18F]FDG-PET病灶检测的临床病理与分子预测因素。基线SUVmax中位7.2,较高SUVmax与更高肿瘤分期、更大肿瘤、淋巴结受累、激素受体阴性、更高HER2蛋白表达、更高Ki67及更高组织学分级相关(p<0.05)。PET[-]标准患者较PET[+]患者肿瘤更小(p=0.014)、无淋巴结受累且组织学分级更低(p<0.01),复发风险(ROR)更低且PAM50 HER2富集亚型比例更低(p<0.05)。

要点

  • 基线SUVmax中位7.2,较高SUVmax与更高肿瘤分期、更大肿瘤及淋巴结受累相关(p<0.05)。
  • PET[-]标准患者较PET[+]患者肿瘤更小(p=0.014)、无淋巴结受累且组织学分级更低(p<0.01)。
  • 42例匹配患者中PET[-]与PET[+]的sTILs水平无差异(p=0.73)。

核心结论

  • 结果凸显HER2阳性乳腺癌的临床、生物学和代谢异质性,可能有助于筛选可能从[18F]FDG-PET成像作为治疗指导工具中获益的HER2阳性早期乳腺癌患者。

研究设计与样本

  • RESPONSE为随机PHERGain试验(NCT03161353)的子研究,纳入500例经MRI评估肿瘤>1.5 cm的HER2阳性早期乳腺癌患者。
  • PET[-]标准为无≥1个乳腺病灶的SUVmax≥1.5×肝脏SUVmean+2个标准差;筛查的75例PET[-]患者中随机选取21例SUVmax<2.5者,按与[18F]FDG-PET状态相关的患者特征与21例SUVmax≥2.5的PET[+]患者匹配。
  • 在基于[18F]FDG-PET入选标准排除与入选的匹配队列中,比较基质肿瘤浸润淋巴细胞(sTILs)及PAM50与Vantage 3D™ Cancer Metabolism Panel基因表达分析。

主要发现

  • 基线SUVmax中位7.2(范围1-39.3)。
  • 全部分析患者中,较高SUVmax与更高肿瘤分期、更大肿瘤尺寸、淋巴结受累、激素受体阴性状态、更高HER2蛋白表达、更高Ki67增殖指数及更高组织学分级相关(p<0.05)。
  • [18F]FDG-PET[-]标准患者较[18F]FDG-PET[+]患者肿瘤尺寸更小(p=0.014)、无淋巴结受累且组织学分级更低(p<0.01)。
  • 42例匹配的[18F]FDG-PET[-]/[+]标准患者间sTILs水平无差异(p=0.73)。
  • [18F]FDG-PET[-]标准患者较[18F]FDG-PET[+]患者复发风险(ROR)更低且PAM50 HER2富集亚型比例更低(p<0.05),两组间癌症代谢相关基因表达存在差异。

关键数值与推荐

  • PET[-]标准:无≥1个乳腺病灶的SUVmax≥1.5×肝脏SUVmean+2个标准差。
  • PET[+]标准:存在≥1个乳腺病灶的SUVmax≥1.5×肝脏SUVmean+2个标准差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PHERGain study (NCT03161353) is assessing early metabolic responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de-escalation using a [18Fluorine]fluorodeoxyglucose-positron emission tomography ([18F]FDG-PET) and a pathological complete response-adapted strategy in HER2-positive (HER2+) early breast cancer (EBC). Herein, we present RESPONSE, a PHERGain substudy, where clinicopathological and molecular predictors of [18F]FDG-PET disease detection were evaluated. METHODS: A total of 500 patients with HER2 + EBC screened in the PHERGain trial with a tumor size > 1.5 cm by magnetic resonance imaging (MRI) were included in the RESPONSE substudy. PET[-] criteria entailed the absence of ≥ 1 breast lesion with maximum standardized uptake value (SUVmax) ≥ 1.5 × SUVmean liver + 2 standard deviation. Among 75 PET[-] patients screened, 21 with SUVmax levels < 2.5 were randomly selected and matched with 21 PET[+] patients with SUVmax levels ≥ 2.5 based on patient characteristics associated with [18F]FDG-PET status. The association between baseline SUVmax and [18F]FDG-PET status ([-] or [+]) with clinicopathological characteristics was assessed. In addition, evaluation of stromal tumor-infiltrating lymphocytes (sTILs) and gene expression analysis using PAM50 and Vantage 3D™ Cancer Metabolism Panel were specifically compared in a matched cohort of excluded and enrolled patients based on the [18F]FDG-PET eligibility criteria. RESULTS: Median SUVmax at baseline was 7.2 (range, 1-39.3). Among all analyzed patients, a higher SUVmax was associated with a higher tumor stage, larger tumor size, lymph node involvement, hormone receptor-negative status, higher HER2 protein expression, increased Ki67 proliferation index, and higher histological grade (p < 0.05). [18F]FDG-PET [-] criteria patients had smaller tumor size (p = 0.014) along with the absence of lymph node involvement and lower histological grade than [18F]FDG-PET [+] patients (p < 0.01). Although no difference in the levels of sTILs was found among 42 matched [18F]FDG-PET [-]/[+] criteria patients (p = 0.73), [18F]FDG-PET [-] criteria patients showed a decreased risk of recurrence (ROR) and a lower proportion of PAM50 HER2-enriched subtype than [18F]FDG-PET[+] patients (p < 0.05). Differences in the expression of genes involved in cancer metabolism were observed between [18F]FDG-PET [-] and [18F]FDG-PET[+] criteria patients. CONCLUSIONS: These results highlight the clinical, biological, and metabolic heterogeneity of HER2+ breast cancer, which may facilitate the selection of HER2+ EBC patients likely to benefit from [18F]FDG-PET imaging as a tool to guide therapy. TRIAL REGISTRATION: Clinicaltrials.gov; NCT03161353; registration date: May 15, 2017.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Llombart-Cussac A, Prat A, Pérez-García JM, et al. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. Eur J Nucl Med Mol Imaging. 2024. PMID: 38587643. doi:10.1007/s00259-024-06683-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。